137 related articles for article (PubMed ID: 36115593)
1. NEK2 inactivates the Hippo pathway to advance the proliferation of cervical cancer cells by cooperating with STRIPAK complexes.
Zhang YR; Zheng PS
Cancer Lett; 2022 Nov; 549():215917. PubMed ID: 36115593
[TBL] [Abstract][Full Text] [Related]
2. Targeting NEK2 impairs oncogenesis and radioresistance via inhibiting the Wnt1/β-catenin signaling pathway in cervical cancer.
Xu T; Zeng Y; Shi L; Yang Q; Chen Y; Wu G; Li G; Xu S
J Exp Clin Cancer Res; 2020 Sep; 39(1):183. PubMed ID: 32907622
[TBL] [Abstract][Full Text] [Related]
3. NIMA related kinase 2 promotes gastric cancer cell proliferation
Fan WD; Chen T; Liu PJ
World J Gastroenterol; 2019 Jun; 25(23):2898-2910. PubMed ID: 31249448
[TBL] [Abstract][Full Text] [Related]
4. NEK2 promotes the migration and proliferation of ESCC via stabilization of YAP1 by phosphorylation at Thr-143.
Su W; Hu H; Ding Q; Wang M; Zhu Y; Zhang Z; Geng Z; Lin S; Zhou P
Cell Commun Signal; 2022 Jun; 20(1):87. PubMed ID: 35705994
[TBL] [Abstract][Full Text] [Related]
5. Role of NIMA-related kinase 2 in lung cancer: Mechanisms and therapeutic prospects.
Shah D; Joshi M; Patel BM
Fundam Clin Pharmacol; 2022 Oct; 36(5):766-776. PubMed ID: 35338518
[TBL] [Abstract][Full Text] [Related]
6. NEK2 Is an Effective Target for Cancer Therapy With Potential to Induce Regression of Multiple Human Malignancies.
Kokuryo T; Yokoyama Y; Yamaguchi J; Tsunoda N; Ebata T; Nagino M
Anticancer Res; 2019 May; 39(5):2251-2258. PubMed ID: 31092416
[TBL] [Abstract][Full Text] [Related]
7. NEK2 enhances malignancies of glioblastoma via NIK/NF-κB pathway.
Xiang J; Alafate W; Wu W; Wang Y; Li X; Xie W; Bai X; Li R; Wang M; Wang J
Cell Death Dis; 2022 Jan; 13(1):58. PubMed ID: 35031599
[TBL] [Abstract][Full Text] [Related]
8. The MST4-MOB4 complex disrupts the MST1-MOB1 complex in the Hippo-YAP pathway and plays a pro-oncogenic role in pancreatic cancer.
Chen M; Zhang H; Shi Z; Li Y; Zhang X; Gao Z; Zhou L; Ma J; Xu Q; Guan J; Cheng Y; Jiao S; Zhou Z
J Biol Chem; 2018 Sep; 293(37):14455-14469. PubMed ID: 30072378
[TBL] [Abstract][Full Text] [Related]
9. The Characteristic of S100A7 Induction by the Hippo-YAP Pathway in Cervical and Glossopharyngeal Squamous Cell Carcinoma.
Kong F; Li Y; Hu E; Wang R; Wang J; Liu J; Zhang J; He D; Xiao X
PLoS One; 2016; 11(12):e0167080. PubMed ID: 27907036
[TBL] [Abstract][Full Text] [Related]
10. microRNA-128-3p overexpression inhibits breast cancer stem cell characteristics through suppression of Wnt signalling pathway by down-regulating NEK2.
Chen Y; Wu N; Liu L; Dong H; Liu X
J Cell Mol Med; 2020 Jul; 24(13):7353-7369. PubMed ID: 32558224
[TBL] [Abstract][Full Text] [Related]
11. STK25 suppresses Hippo signaling by regulating SAV1-STRIPAK antagonism.
Bae SJ; Ni L; Luo X
Elife; 2020 Apr; 9():. PubMed ID: 32292165
[TBL] [Abstract][Full Text] [Related]
12. Calmodulin activates the Hippo signaling pathway by promoting LATS1 kinase-mediated inhibitory phosphorylation of the transcriptional coactivator YAP.
Thines L; Gorisse L; Li Z; Sayedyahossein S; Sacks DB
J Biol Chem; 2022 May; 298(5):101839. PubMed ID: 35307353
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer.
Zeng YR; Han ZD; Wang C; Cai C; Huang YQ; Luo HW; Liu ZZ; Zhuo YJ; Dai QS; Zhao HB; Liang YX; Zhong WD
BMC Urol; 2015 Aug; 15():90. PubMed ID: 26320076
[TBL] [Abstract][Full Text] [Related]
14. Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma.
Wong KF; Liu AM; Hong W; Xu Z; Luk JM
Oncotarget; 2016 Nov; 7(47):77683-77695. PubMed ID: 27765911
[TBL] [Abstract][Full Text] [Related]
15. CGK062, a small chemical molecule, inhibits cancer upregulated gene 2‑induced oncogenesis through NEK2 and β‑catenin.
Kaowinn S; Oh S; Moon J; Yoo AY; Kang HY; Lee MR; Kim JE; Hwang DY; Youn SE; Koh SS; Chung YH
Int J Oncol; 2019 Apr; 54(4):1295-1305. PubMed ID: 30968157
[TBL] [Abstract][Full Text] [Related]
16. Targeting NEK2 as a promising therapeutic approach for cancer treatment.
Fang Y; Zhang X
Cell Cycle; 2016; 15(7):895-907. PubMed ID: 27019372
[TBL] [Abstract][Full Text] [Related]
17. NEK2 promotes hepatocellular carcinoma migration and invasion through modulation of the epithelial-mesenchymal transition.
Zhang Y; Wang W; Wang Y; Huang X; Zhang Z; Chen B; Xie W; Li S; Shen S; Peng B
Oncol Rep; 2018 Mar; 39(3):1023-1033. PubMed ID: 29399700
[TBL] [Abstract][Full Text] [Related]
18. Silencing of Nek2 suppresses the proliferation, migration and invasion and induces apoptosis of breast cancer cells by regulating ERK/MAPK signaling.
Xing Z; Zhang M; Wang X; Liu J; Liu G; Feng K; Wang X
J Mol Histol; 2021 Aug; 52(4):809-821. PubMed ID: 34009515
[TBL] [Abstract][Full Text] [Related]
19. Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK/T cell lymphoma cells.
Chang Y; Fu XR; Cui M; Li WM; Zhang L; Li X; Li L; Sun ZC; Zhang XD; Li ZM; You XY; Nan FF; Wu JJ; Wang XH; Zhang MZ
Cancer Med; 2019 Jul; 8(8):3892-3904. PubMed ID: 31124291
[TBL] [Abstract][Full Text] [Related]
20. NEK2 Promotes Hepatoma Metastasis and Serves as Biomarker for High Recurrence Risk after Hepatic Resection.
Chang YY; Yen CJ; Chan SH; Chou YW; Lee YP; Bao CY; Huang CJ; Huang W
Ann Hepatol; 2018 Aug; 17(5):843-856. PubMed ID: 30145571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
